PL393584A1 - Szczepionka - Google Patents

Szczepionka

Info

Publication number
PL393584A1
PL393584A1 PL393584A PL39358401A PL393584A1 PL 393584 A1 PL393584 A1 PL 393584A1 PL 393584 A PL393584 A PL 393584A PL 39358401 A PL39358401 A PL 39358401A PL 393584 A1 PL393584 A1 PL 393584A1
Authority
PL
Poland
Prior art keywords
vaccine
influenzae
conjugate
toxoid
whole
Prior art date
Application number
PL393584A
Other languages
English (en)
Inventor
Dominique Boutriau
Carine Capiau
Pierre Michel Desmons
Dominique Lemoine
Jan Poolman
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL393584(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0015999.6A external-priority patent/GB0015999D0/en
Priority claimed from GB0108363A external-priority patent/GB0108363D0/en
Priority claimed from GBGB0108364.1A external-priority patent/GB0108364D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL393584A1 publication Critical patent/PL393584A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL393584A 2000-06-29 2001-06-27 Szczepionka PL393584A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0015999.6A GB0015999D0 (en) 2000-06-29 2000-06-29 Novel compounds
GB0108363A GB0108363D0 (en) 2001-04-03 2001-04-03 Vaccine composition
GBGB0108364.1A GB0108364D0 (en) 2001-04-03 2001-04-03 Vaccine composition

Publications (1)

Publication Number Publication Date
PL393584A1 true PL393584A1 (pl) 2011-05-23

Family

ID=27255788

Family Applications (2)

Application Number Title Priority Date Filing Date
PL393584A PL393584A1 (pl) 2000-06-29 2001-06-27 Szczepionka
PL360265A PL210015B1 (pl) 2000-06-29 2001-06-27 Wieloważna kompozycja immunogenna, jej zastosowanie i sposób wytwarzania tej kompozycji

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL360265A PL210015B1 (pl) 2000-06-29 2001-06-27 Wieloważna kompozycja immunogenna, jej zastosowanie i sposób wytwarzania tej kompozycji

Country Status (34)

Country Link
US (2) US20030180316A1 (pl)
EP (4) EP2279748A1 (pl)
JP (2) JP4870895B2 (pl)
KR (3) KR20070091698A (pl)
CN (2) CN1449293B (pl)
AP (1) AP1695A (pl)
AT (1) ATE534402T1 (pl)
AU (2) AU2001281895C1 (pl)
BG (2) BG66238B1 (pl)
BR (2) BR122012003821B8 (pl)
CA (2) CA2783274C (pl)
CY (2) CY1112280T1 (pl)
CZ (1) CZ20024224A3 (pl)
DK (2) DK1296715T4 (pl)
DZ (1) DZ3399A1 (pl)
EA (2) EA006313B1 (pl)
EG (1) EG24742A (pl)
ES (2) ES2385100T3 (pl)
HU (3) HU227893B1 (pl)
IL (2) IL153506A0 (pl)
MA (1) MA25824A1 (pl)
MX (1) MXPA03000198A (pl)
MY (1) MY133981A (pl)
NO (1) NO332495B1 (pl)
NZ (1) NZ523319A (pl)
OA (1) OA12302A (pl)
PE (1) PE20020126A1 (pl)
PL (2) PL393584A1 (pl)
PT (2) PT1296715E (pl)
SI (2) SI1296715T2 (pl)
SK (1) SK288007B6 (pl)
UA (2) UA76952C2 (pl)
UY (1) UY26801A1 (pl)
WO (1) WO2002000249A2 (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540795B2 (ja) * 2000-03-10 2010-09-08 一般財団法人阪大微生物病研究会 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
DK1355673T3 (da) 2001-01-23 2012-09-17 Sanofi Pasteur Inc Multivalent meningococvaccine bestående af et polysaccharid/proteinkonjugat
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
EP2332573A1 (en) 2001-05-31 2011-06-15 Novartis Vaccines and Diagnostics, Inc. Chimeric alphavirus replicon particles
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
WO2004039399A1 (en) * 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CA2524853A1 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
MXPA05014171A (es) * 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1961426B1 (en) * 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
CU23404A1 (es) * 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
CN1709505B (zh) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR20080079697A (ko) * 2005-12-23 2008-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 컨쥬게이트 백신
JP5275814B2 (ja) * 2006-01-17 2013-08-28 フオルスレン，アルネ 新規表面露出ヘモフィルス・インフルエンザ（ＨＡＥＭＯＰＨＩＬＵＳＩＮＦＬＵＥＮＺＡＥ）タンパク質（タンパク質Ｅ；ｐＥ）
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
PT2097102E (pt) * 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
IN2009KN04098A (pl) 2007-06-04 2015-08-28 Novartis Ag
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
ES2614807T3 (es) * 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
AU2011343367B2 (en) 2010-12-14 2015-05-21 Glaxosmithkline Biologicals S.A. Mycobacterium antigenic composition
BR112013017171B1 (pt) 2011-01-05 2019-12-17 Bharat Biotech International Limited composição combinada heptavalente estável
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
SI2809349T1 (sl) * 2012-01-30 2019-03-29 Serum Institute Of India Private Limited Imunogeni sestavek
JP2015509963A (ja) * 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
SG11201502635SA (en) * 2012-10-17 2015-05-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
DK2863943T3 (en) 2013-03-08 2016-11-07 Janssen Vaccines & Prevention Bv acellular pertussis vaccines
KR102250099B1 (ko) * 2013-07-07 2021-05-10 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 스트렙토코커스 뉴모니에 1형에 대한 합성 백신
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
JP7001686B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
LT3506935T (lt) 2016-09-02 2024-04-25 Sanofi Pasteur, Inc. Vakcina nuo neisseria meningitidis
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102812816B1 (ko) 2018-02-05 2025-05-27 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
IL276230B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US11896656B2 (en) * 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20200005458A (ko) 2018-07-06 2020-01-15 주식회사 유바이오로직스 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.
BR112021011961A8 (pt) 2018-12-19 2023-02-07 Merck Sharp & Dohme Composições compreendendo conjugados de polissacarídeo-proteína de streptococcus pneumoniae e métodos de uso dos mesmos
GB2619625B (en) 2019-05-20 2024-04-03 Soligenix Inc Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
CN111821432B (zh) * 2020-08-05 2022-10-18 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合疫苗
WO2025109417A1 (en) * 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) * 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
JPS6061288A (ja) * 1983-09-13 1985-04-09 Fuji Photo Film Co Ltd 感熱記録材料
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
EP0835663B1 (en) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens
ATE188508T1 (de) 1992-06-18 2000-01-15 Harvard College Impfstoffe gegen diphtherietoxin
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0594950T3 (da) * 1992-10-27 1999-09-13 American Cyanamid Co Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69612198T3 (de) * 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
EP0973911A1 (en) 1997-01-30 2000-01-26 Imperial College Of Science, Technology & Medicine MUTANT $i(msbB) or $i(htrB) GENES
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
KR20130122810A (ko) * 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR20080079697A (ko) * 2005-12-23 2008-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 컨쥬게이트 백신
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008111374A1 (ja) * 2007-03-14 2008-09-18 Konica Minolta Business Technologies, Inc. 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
JP2010525035A (ja) * 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
IN2009KN04098A (pl) * 2007-06-04 2015-08-28 Novartis Ag
PL2167121T3 (pl) * 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae

Also Published As

Publication number Publication date
CA2412497C (en) 2012-10-02
SI1296715T1 (sl) 2012-03-30
SK18432002A3 (sk) 2003-08-05
CA2783274A1 (en) 2002-01-03
BG107422A (bg) 2003-09-30
PE20020126A1 (es) 2002-04-27
CN101708333A (zh) 2010-05-19
HUP0301413A3 (en) 2010-01-28
PL210015B1 (pl) 2011-11-30
AU2001281895C1 (en) 2005-10-27
EP2277541A1 (en) 2011-01-26
CA2412497A1 (en) 2002-01-03
OA12302A (en) 2003-10-24
NO20026175D0 (no) 2002-12-20
EP1296715B1 (en) 2011-11-23
CA2783274C (en) 2018-08-07
NZ523319A (en) 2006-01-27
EP1296715A2 (en) 2003-04-02
KR20080052700A (ko) 2008-06-11
HU1000594D0 (en) 2010-12-28
CN1449293B (zh) 2012-08-22
JP4870895B2 (ja) 2012-02-08
US20120207780A1 (en) 2012-08-16
US20030180316A1 (en) 2003-09-25
CN1449293A (zh) 2003-10-15
HU227893B1 (en) 2012-05-29
CY1112915T1 (el) 2016-04-13
HK1055244A1 (en) 2004-01-02
JP5346308B2 (ja) 2013-11-20
EA006313B1 (ru) 2005-10-27
BG66238B1 (bg) 2012-08-31
WO2002000249A3 (en) 2002-06-13
SI1296715T2 (sl) 2016-03-31
CN101708333B (zh) 2014-03-26
PT1946769E (pt) 2012-06-27
DK1946769T3 (da) 2012-07-16
BG66249B1 (en) 2012-09-28
US9233151B2 (en) 2016-01-12
BR122012003821B8 (pt) 2021-05-25
SK288007B6 (sk) 2012-10-02
BR0112057A (pt) 2003-06-17
EP2279748A1 (en) 2011-02-02
ES2375704T5 (es) 2016-03-03
DZ3399A1 (fr) 2002-01-03
HU1000593D0 (en) 2010-12-28
DK1296715T4 (en) 2016-03-07
SI1946769T1 (sl) 2012-07-31
KR100898845B1 (ko) 2009-05-21
EG24742A (en) 2010-07-14
EP1296715B2 (en) 2015-12-23
BR122012003821B1 (pt) 2020-09-01
HU228384B1 (en) 2013-03-28
EA011480B1 (ru) 2009-04-28
ATE534402T1 (de) 2011-12-15
CZ20024224A3 (cs) 2003-05-14
KR20070091698A (ko) 2007-09-11
UA76952C2 (uk) 2006-10-16
AP1695A (en) 2006-12-17
AU2001281895B2 (en) 2005-04-28
HUP0301413A1 (hu) 2003-08-28
EP1946769B1 (en) 2012-05-30
EA200501070A1 (ru) 2006-02-24
BG110518A (bg) 2010-04-30
PL360265A1 (pl) 2004-09-06
UY26801A1 (es) 2002-01-31
HU227613B1 (en) 2011-09-28
UA85853C2 (uk) 2009-03-10
AU8189501A (en) 2002-01-08
ES2385100T3 (es) 2012-07-18
AP2002002700A0 (en) 2002-12-31
MA25824A1 (fr) 2003-07-01
NO20026175L (no) 2003-02-26
WO2002000249A2 (en) 2002-01-03
PT1296715E (pt) 2012-01-19
KR20030024714A (ko) 2003-03-26
ES2375704T3 (es) 2012-03-05
EP1946769A3 (en) 2008-07-30
CY1112280T1 (el) 2015-12-09
MY133981A (en) 2007-11-30
JP2004501873A (ja) 2004-01-22
DK1296715T3 (da) 2012-02-13
BRPI0112057B1 (pt) 2016-10-04
BRPI0112057B8 (pt) 2021-05-25
KR100837917B1 (ko) 2008-06-13
NO332495B1 (no) 2012-10-01
IL153506A (en) 2009-06-15
EA200201240A1 (ru) 2003-06-26
EP1946769A2 (en) 2008-07-23
JP2010163453A (ja) 2010-07-29
MXPA03000198A (es) 2004-09-13
IL153506A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
HU1000594D0 (en) Vaccine composition
EP0914153B8 (en) Multivalent dtp-polio vaccines
GB9713156D0 (en) Vaccines
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
AU4707097A (en) Multivalent vaccines
GB0405787D0 (en) Low dose vaccines
PL1835939T3 (pl) Skoniugowane szczepionki przeciwko meningokokom
DK1240905T3 (da) Acellulær pertussisvaccine med difteri- og tetanustoksoider
HUT67239A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
CA2366316A1 (en) Multi-component vaccine comprising at least three antigens to protect against disease caused by haemophilus influenzae
AU3318289A (en) Pertussis toxoid vaccine

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)